home        Services        Antibody Therapeutics Discovery
Antibody Therapeutics Discovery

As a technology and innovation driven contract research biotech company, Viva has established a comprehensive antibody therapeutic platform, including a in-house developed Naïve human scFV phage display library with 11 billions collection, hybridoma generation, protein engineering, epitope mapping, antibody humanization and affinity maturation, stable cell line generation and optimization etc.

In-house Naïve Human scFv Phage Display Library:

■ Naïve antibody genes from >50 human donors (Spleens and Bone marrows)

■ Naïve library

size: 1.1x1010

○ Sequence diversity analysis

○ 16/64: truncation, frameshift, amber codon

○ 46/64: full length scFv, all HCDR3s are unique

13/46: lamda LC

33/46: kappa LC

■ Library selection

○ Applied to more 10 protein antigens

○ 20-200 unique antibody clones/antigen

Best affinity: 0.5 nM; usually: 10-100 nM

 Antibody Drug Discovery:


Reagent antibody provision:

■ Immunogen: peptide, recombinant protein, etc

■ Antibody generation

○ Hybridoma approach

○ Phage display approach

■ Antibody affinity maturation

○ CDR mutagenesis

○ Chain shuffling

○ Error-prone PCR

■ Production

In vivo production

○ In vitro production using mammalian expression system